Vaccination in systemic lupus erythematosus.

Area of Science:

• Immunology
• Rheumatology
• Infectious Disease

Background:

• Infection is a primary cause of mortality in systemic lupus erythematosus (SLE) patients.
• Vaccination is a key strategy to mitigate infection risk in this vulnerable population.

Purpose of the Study:

• To review the current evidence on vaccination strategies for patients with SLE.
• To evaluate vaccine immunogenicity, safety, and optimal timing in SLE management.

Main Methods:

• Literature review of studies on vaccine response in SLE patients.
• Analysis of data regarding immunogenicity of various vaccines (e.g., SARS-CoV2, influenza, pneumococcal).
• Assessment of SLE flare risk post-vaccination and considerations for immunosuppressed individuals.

Main Results:

• Most SLE patients achieve adequate immune responses to SARS-CoV2 vaccines, but lower immunogenicity is seen with influenza and pneumococcal vaccines.
• Current evidence does not link common vaccines to an increased risk of SLE flares.
• Vaccine responses are attenuated in patients receiving intense immunosuppression or B-cell depleting therapies.

Conclusions:

• Individualized vaccination decisions are necessary for SLE patients, balancing risks and benefits.
• Vaccination is recommended during periods of low disease activity or remission.
• Live vaccines are less preferred than inactivated or recombinant vaccines for immunosuppressed SLE patients; adjunctive measures may be considered.